Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

• Published in: British journal of cancer 2018-03, Vol.118 (5), p.679-697
• Main Authors: Viala, Marie, Vinches, Marie, Alexandre, Marie, Mollevi, Caroline, Durigova, Anna, Hayaoui, Nadia, Homicsko, Krisztian, Cuenant, Alice, Gongora, Céline, Gianni, Luca, Tosi, Diego
• Format: Article
• Language: English
• Subjects: 692/308/153; 692/4028/67/1059/153; Antibodies, Monoclonal; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Clinical Decision-Making; Clinical trials; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug dosages; Drug Resistance; Epidemiology; FDA approval; Humans; Immunology; Immunotherapy; Life Sciences; Molecular Medicine; Monoclonal antibodies; Neoplasms; Neoplasms - drug therapy; Oncology; Pharmaceutical sciences; Pharmacology; Research Design; Toxicity; Translational Therapeutics
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.2017.473

Background: Our previous survey on first-in-human trials (FIHT) of monoclonal antibodies (mAbs) showed that, due to their limited toxicity, the recommended phase II dose (RP2D) was only tentatively defined. Methods: We identified, by MEDLINE search, articles on single-agent trials of mAbs with an FIHT included in our previous survey. For each mAb, we examined tested dose(s) and dose selection rationale in non-FIHTs (NFIHTs). We also assessed the correlation between doses tested in the registration trials (RTs) of all FDA-approved mAbs and the corresponding FIHT results. Results: In the 37 dose-escalation NFIHTs, the RP2D indication was still poorly defined. In phase II–III NFIHTs ( n =103 on 37 mAbs), the FIHT RP2D was the only dose tested for five mAbs. For 16 mAbs, only doses different from the FIHT RP2D or the maximum administered dose (MAD) were tested and the dose selection rationale infrequently indicated. In the 60 RTs on 27 FDA-approved mAbs with available FIHT, the FIHT RP2D was tested only for two mAbs, and RT doses were much lower than the FIHT MAD. Conclusions: The rationale beyond dose selection in phase II and III trials of mAbs is often unclear in published articles and not based on FIHT data.